284 related articles for article (PubMed ID: 19662088)
1. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.
Takakura M; Nakamura M; Kyo S; Hashimoto M; Mori N; Ikoma T; Mizumoto Y; Fujiwara T; Urata Y; Inoue M
Cancer Gene Ther; 2010 Jan; 17(1):11-9. PubMed ID: 19662088
[TBL] [Abstract][Full Text] [Related]
2. A novel CRAd in combination with cisplatin enhanced the antitumor efficacy in ovarian cancer.
Zhang B; Liu Y; Zhang P; Wei Y; Yin X; Zheng J
Int J Gynecol Cancer; 2011 Dec; 21(9):1540-6. PubMed ID: 22080895
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of telomerase-specific replication-selective oncolytic viruses for adenoid cystic carcinoma cell lines.
Sato D; Kurihara Y; Kondo S; Shirota T; Urata Y; Fujiwara T; Shintani S
Oncol Rep; 2013 Dec; 30(6):2659-64. PubMed ID: 24065118
[TBL] [Abstract][Full Text] [Related]
4. Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses.
Kishimoto H; Urata Y; Tanaka N; Fujiwara T; Hoffman RM
Mol Cancer Ther; 2009 Nov; 8(11):3001-8. PubMed ID: 19887549
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy.
Fujiwara T; Kagawa S; Kishimoto H; Endo Y; Hioki M; Ikeda Y; Sakai R; Urata Y; Tanaka N; Fujiwara T
Int J Cancer; 2006 Jul; 119(2):432-40. PubMed ID: 16477640
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma.
Kondo N; Tsukuda M; Kimura M; Fujita K; Sakakibara A; Takahashi H; Ishiguro Y; Toth G; Matsuda H
Oncol Rep; 2010 Feb; 23(2):355-63. PubMed ID: 20043095
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer.
Sakai R; Kagawa S; Yamasaki Y; Kojima T; Uno F; Hashimoto Y; Watanabe Y; Urata Y; Tanaka N; Fujiwara T
Mol Cancer Ther; 2010 Jun; 9(6):1884-93. PubMed ID: 20501801
[TBL] [Abstract][Full Text] [Related]
9. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
[TBL] [Abstract][Full Text] [Related]
10. Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery.
Kuroda S; Fujiwara T; Shirakawa Y; Yamasaki Y; Yano S; Uno F; Tazawa H; Hashimoto Y; Watanabe Y; Noma K; Urata Y; Kagawa S; Fujiwara T
Cancer Res; 2010 Nov; 70(22):9339-48. PubMed ID: 21045143
[TBL] [Abstract][Full Text] [Related]
11. Telomerase-specific virotheranostics for human head and neck cancer.
Kurihara Y; Watanabe Y; Onimatsu H; Kojima T; Shirota T; Hatori M; Liu D; Kyo S; Mizuguchi H; Urata Y; Shintani S; Fujiwara T
Clin Cancer Res; 2009 Apr; 15(7):2335-43. PubMed ID: 19318473
[TBL] [Abstract][Full Text] [Related]
12. [Theranostic application of telomerase-specific oncolytic adenovirus for human cancer].
Fujiwara T; Tanaka N
Nihon Rinsho; 2007 Oct; 65(10):1913-22. PubMed ID: 17926546
[TBL] [Abstract][Full Text] [Related]
13. Fluorescence-guided assessment of bone and soft-tissue sarcomas for predicting the efficacy of telomerase-specific oncolytic adenovirus.
Uotani K; Tazawa H; Hasei J; Fujiwara T; Yoshida A; Yamakawa Y; Omori T; Sugiu K; Komatsubara T; Kondo H; Morita T; Kiyono M; Yokoo S; Hata T; Kunisada T; Takeda K; Urata Y; Fujiwara T; Ozaki T
PLoS One; 2024; 19(2):e0298292. PubMed ID: 38377118
[TBL] [Abstract][Full Text] [Related]
14. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.
Fujiwara T; Tanaka N
Uirusu; 2008 Jun; 58(1):11-8. PubMed ID: 19122384
[TBL] [Abstract][Full Text] [Related]
15. Real-Time Fluorescence Image-Guided Oncolytic Virotherapy for Precise Cancer Treatment.
Yano S; Tazawa H; Kishimoto H; Kagawa S; Fujiwara T; Hoffman RM
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477279
[TBL] [Abstract][Full Text] [Related]
16. Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer.
Rein DT; Volkmer A; Bauerschmitz G; Beyer IM; Janni W; Fleisch MC; Welter AK; Bauerschlag D; Schöndorf T; Breidenbach M
J Cancer Res Clin Oncol; 2012 Apr; 138(4):603-10. PubMed ID: 22209976
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
[TBL] [Abstract][Full Text] [Related]
18. [Construction of autocatalytic caspase-3 driven by amplified human telomerase reverse transcriptase promoter and its enhanced efficacy of inducing apoptosis in human ovarian carcinoma].
Song Y; Shen K; He CX
Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):617-22. PubMed ID: 17983518
[TBL] [Abstract][Full Text] [Related]
19. [Oncolytic virotherapy for human solid tumors].
Fujiwara T
Gan To Kagaku Ryoho; 2009 May; 36(5):703-9. PubMed ID: 19461167
[TBL] [Abstract][Full Text] [Related]
20. Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma.
Mochizuki Y; Tazawa H; Demiya K; Kure M; Kondo H; Komatsubara T; Sugiu K; Hasei J; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Immunol Immunother; 2021 May; 70(5):1405-1417. PubMed ID: 33151368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
